A Bioartificial Device for the Encapsulation of Pancreatic β-Cells Using a Semipermeable Biocompatible Porous Membrane DOI Open Access
Nicola Cuscino, Salvatore Castelbuono,

Claudio Centi

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1631 - 1631

Published: Feb. 27, 2025

Background/Objectives: Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by the destruction of pancreatic β-cells, leading to insulin deficiency. Current therapies, such as islet transplantation, face significant challenges, including limited donor availability and need for lifelong immunosuppression. Encapsulation technologies offer promising alternative, providing immune protection maintaining β-cell viability. In this study, we propose an encapsulation device featuring spiral tubular semipermeable polyethersulfone (PES) membrane reinforced with rigid biocompatible resin scaffold. Methods: The PES was engineered tailored porosity 0.5 µm, enabling efficient nutrient oxygen exchange while preventing cell infiltration. Using INS-1E insulin-secreting cells aggregated into size-controlled islet-like spheroids (ILSs), evaluated device’s performance. Results: achieved high ILS viability secretion over 48 h at therapeutic densities, functionality comparable free-floating ILSs (control). membrane, its mechanical stability biocompatibility, ensured durability without compromising diffusion dynamics, overcoming critical limitation other approaches. Importantly, geometry allowed up 356,000 equivalents (IEQs) in single capillary fiber, reaching thresholds T1D patients. Conclusions: device, innovative design, enables high-density preserving scalability, making it potential platform clinical application. This work highlights PES-based devices overcome key barriers treatment, paving way personalized, long-term solutions restore independence.

Language: Английский

A Bioartificial Device for the Encapsulation of Pancreatic β-Cells Using a Semipermeable Biocompatible Porous Membrane DOI Open Access
Nicola Cuscino, Salvatore Castelbuono,

Claudio Centi

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1631 - 1631

Published: Feb. 27, 2025

Background/Objectives: Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by the destruction of pancreatic β-cells, leading to insulin deficiency. Current therapies, such as islet transplantation, face significant challenges, including limited donor availability and need for lifelong immunosuppression. Encapsulation technologies offer promising alternative, providing immune protection maintaining β-cell viability. In this study, we propose an encapsulation device featuring spiral tubular semipermeable polyethersulfone (PES) membrane reinforced with rigid biocompatible resin scaffold. Methods: The PES was engineered tailored porosity 0.5 µm, enabling efficient nutrient oxygen exchange while preventing cell infiltration. Using INS-1E insulin-secreting cells aggregated into size-controlled islet-like spheroids (ILSs), evaluated device’s performance. Results: achieved high ILS viability secretion over 48 h at therapeutic densities, functionality comparable free-floating ILSs (control). membrane, its mechanical stability biocompatibility, ensured durability without compromising diffusion dynamics, overcoming critical limitation other approaches. Importantly, geometry allowed up 356,000 equivalents (IEQs) in single capillary fiber, reaching thresholds T1D patients. Conclusions: device, innovative design, enables high-density preserving scalability, making it potential platform clinical application. This work highlights PES-based devices overcome key barriers treatment, paving way personalized, long-term solutions restore independence.

Language: Английский

Citations

0